ArticleFrontiers in pharmacology2025

Cost-effectiveness evaluation of benmelstobart, anlotinib and chemotherapy in patients with extensive-stage small-cell lung cancer.

Jing Nie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.